Developing New Drugs
to Address Unmet Medical Needs 

An experienced global R&D team in disease area associated with bacterial infections and metabolism

Multi-Targeting Drug Conjugate Technology and a Strong R&D Pipeline with Global IP Protection

Multiple products entering late-stage of clinical development with indications such as Helicobacter pylori infection, implanted medical device infection, liver cirrhotic hepatic encephalopathy, and irritable bowel syndrome with diarrhea